Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

Eli Lilly’s New GLP-1 Pill Posts Better-Than-Expected Results

The experimental drug, orforglipron, led to weight loss of nearly 8 percent at the highest dose, besting Wall Street expectations and sending Lilly’s shares up.
Famed for speedy weight loss, Ozempic is having far-reaching consequences.
Famed for speedy weight loss, Ozempic is having far-reaching consequences. (Shutterstock)

Eli Lilly’s experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.

In This Article

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

More from Beauty
Analysis and advice on the fast-evolving beauty business.
view more
Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.

What Stops Beauty Shoppers From Buying More

Beauty brands must rethink upselling with smarter value plays, from curated bundles to jumbo sizes and subscriptions, to keep their customers from switching to the competition.


Who Won Fashion’s Red Carpet Season of Change

Sunday night’s Oscars concluded an awards season that fashion’s biggest labels used to show off their new creative game. BoF breaks down what we learned about brands’ celebrity strategies.


VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON